To investigate the in vivo effects of the ATRA/EGFR inhibitor combination, we first assessed the protein levels of Egfr in APL blasts from the transgenic hCG-PML-RARA mice (pool of leukemic blast cells, n=5; Figure S3B). Here, EGFR is linked to acute promyelocytic leukemia.